Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Terazosin
Drug ID BADD_D02158
Description Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].
Indications and Usage Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label].
Marketing Status approved
ATC Code G04CA03
DrugBank ID DB01162
KEGG ID D08569
MeSH ID C041226
PubChem ID 5401
TTD Drug ID D0P9RF
NDC Product Code 51655-915; 68788-8171; 70518-3211; 70518-3193; 23155-738; 67296-1264; 23155-736; 62135-460; 70518-3272; 62135-459; 23155-735; 23155-737; 71335-9607; 60760-816; 62135-458; 62135-461
UNII 8L5014XET7
Synonyms Terazosin | Adecur | Apo-Terazosin | Dysalfa | Hytrin | Flotrin | Hytrin BPH | Hytrine | Heitrin | Deflox | Magnurol | Novo-Terazosin | Nu-Terazosin | PMS-Terazosin | terazosin hydrochloride anhydrous | Sutif | Tazusin | Terazoflo | Terazosin AZU | Terazosin Hexal | Terazosin hydrochloride | terazosin, monohydrochloride, dihydrate | Terazosina Alter | Terazosina Kern | Terazosina Qualix | Zayasel | A 45975 | ratio-Terazosin
Chemical Information
Molecular Formula C19H25N5O4
CAS Registry Number 63590-64-7
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.0020.001918%
Influenza22.07.02.001; 11.05.03.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Laryngospasm22.04.02.002--
Libido decreased21.03.02.005; 19.08.03.001--
Lip oedema23.04.01.006; 10.01.05.004; 07.05.04.0040.000112%Not Available
Loss of consciousness17.02.04.0040.000580%Not Available
Loss of libido19.08.03.003--Not Available
Malaise08.01.01.0030.000167%
Menopause26.03.01.001--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Miosis17.02.11.002; 06.05.03.003--Not Available
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.0010.000357%
Neck pain15.03.04.009--
Nervousness19.06.02.003--Not Available
Nocturia20.02.03.0010.000245%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Orthostatic hypotension17.05.01.020; 24.06.03.0040.001026%Not Available
Osteoarthritis15.01.04.001--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Penile pain21.12.01.0080.000379%
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages